Laser treatment for lipoatrophy in children with diabetes type 1

Xatzipsalti, Maria; Alvertis, Hlias; Vazeou, Andriani

doi:10.1007/s13340-021-00547-w

Cited by 2 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 months following treatment, a dramatic reversal of LA sites on the buttocks was observed, whereas the LA site of the right upper thigh showed little to no improvement where SCG treatment was continued [28]. A largely identical treatment course was further discussed in a 9-year-old patient by the same authors [28].…”

Section: Lipodystrophiesmentioning

confidence: 92%

“…LA did not improve after switching to insulin glulisine or with the administration of 4% sodium chromoglycate (SCG) [28]. Due to the failure of conservative treatments, a CO2 laser, which generates a D-pulse that targets deep subcutaneous tissue, was directed at sites of LA on the bilateral buttocks [28]. 9 months following treatment, a dramatic reversal of LA sites on the buttocks was observed, whereas the LA site of the right upper thigh showed little to no improvement where SCG treatment was continued [28].…”

Section: Lipodystrophiesmentioning

confidence: 99%

“…First, a 6-year-old child was found to have sites of LA on the right upper thigh and bilateral buttocks. LA did not improve after switching to insulin glulisine or with the administration of 4% sodium chromoglycate (SCG) [28]. Due to the failure of conservative treatments, a CO2 laser, which generates a D-pulse that targets deep subcutaneous tissue, was directed at sites of LA on the bilateral buttocks [28].…”

Section: Lipodystrophiesmentioning

confidence: 99%

“…Due to the failure of conservative treatments, a CO2 laser, which generates a D-pulse that targets deep subcutaneous tissue, was directed at sites of LA on the bilateral buttocks [28]. 9 months following treatment, a dramatic reversal of LA sites on the buttocks was observed, whereas the LA site of the right upper thigh showed little to no improvement where SCG treatment was continued [28]. A largely identical treatment course was further discussed in a 9-year-old patient by the same authors [28].…”

Section: Lipodystrophiesmentioning

confidence: 99%

“…Despite these measures, some patients are still unable to tolerate these effects, leading to discontinued use. Interventions such as laser therapy should be further explored to restore and optimize surface area for device use and insulin administration [28].…”

Section: Other Skin Manifestationsmentioning

confidence: 99%

See 4 more Smart Citations

Cutaneous Adverse Effects from Diabetes Devices in Pediatric Patients with Type 1 Diabetes Mellitus: a Systematic Review (Preprint)

Podwojniak,

Flemming,

Tan

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSII) are the current standard treatment devices for type 1 diabetes (T1D) management. With a high prevalence of T1D beginning in pediatrics and carrying into adulthood, insufficient glycemic control leads to poor patient outcomes. Dermatologic complications such as contact dermatitis, lipodystrophies, and inflammatory lesions are among those associated with CGM and CSII, which reduce glycemic control and patient compliance. OBJECTIVE This systematic review aims to explore the current literature surrounding dermatologic complications of CGM, CSII, and the impact on patient outcomes. METHODS A systematic review of the literature was carried out using PRISMA 2020 guidelines utilizing five online databases. Included articles were those containing primary data relevant to human subjects and adverse CGM and CSII devices in pediatric populations of which greater than 50% of the sample size were ages 0-21. Qualitative analysis was chosen due to the heterogeneity of outcomes. RESULTS Following the application of exclusion criteria, 25 studies were analyzed and discussed. The most common complication covered is contact dermatitis with 12 identified studies. 6 studies concern lipodystrophies, 4 cover nonspecific cutaneous changes, and the remaining 3 cover unique cutaneous findings such as granulomatous reactions and panniculitis. CONCLUSIONS The dermatologic complications of CGM and CSII pose a potential risk to long-term glycemic control in T1D, especially in young patients where skin lesions can lead to discontinuation. Increased manufacturer transparency is critical and further studies are needed to expand upon the current preventative measures such as device site rotation and steroid creams, which lack consistent effectiveness.

show abstract

Section: Lipodystrophiesmentioning

confidence: 92%

Section: Lipodystrophiesmentioning

confidence: 99%

Section: Lipodystrophiesmentioning

confidence: 99%

Section: Lipodystrophiesmentioning

confidence: 99%

Section: Other Skin Manifestationsmentioning

confidence: 99%

See 3 more Smart Citations

Cutaneous Adverse Effects from Diabetes Devices in Pediatric Patients with Type 1 Diabetes Mellitus: a Systematic Review (Preprint)

Podwojniak,

Flemming,

Tan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Cutaneous Adverse Effects from Diabetes Devices in Pediatric Patients with Type 1 Diabetes Mellitus: a Systematic Review (Preprint)

Podwojniak,

Flemming,

Tan

et al. 2024

JMIR Dermatology

View full text Add to dashboard Cite

Background: Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSII) are the current standard treatment devices for type 1 diabetes (T1D) management. With a high prevalence of T1D beginning in pediatrics and carrying into adulthood, insufficient glycemic control leads to poor patient outcomes. Dermatologic complications such as contact dermatitis, lipodystrophies, and inflammatory lesions are among those associated with CGM and CSII, which reduce glycemic control and patient compliance.Objective: This systematic review aims to explore the current literature surrounding dermatologic complications of CGM, CSII, and the impact on patient outcomes. Methods:A systematic review of the literature was carried out using PRISMA 2020 guidelines utilizing five online databases. Included articles were those containing primary data relevant to human subjects and adverse CGM and CSII devices in pediatric populations of which greater than 50% of the sample size were ages 0-21. Qualitative analysis was chosen due to the heterogeneity of outcomes.Results: Following the application of exclusion criteria, 25 studies were analyzed and discussed. The most common complication covered is contact dermatitis with 12 identified studies. 6 studies concern lipodystrophies, 4 cover nonspecific cutaneous changes, and the remaining 3 cover unique cutaneous findings such as granulomatous reactions and panniculitis. Conclusions:The dermatologic complications of CGM and CSII pose a potential risk to long-term glycemic control in T1D, especially in young patients where skin lesions can lead to discontinuation. Increased manufacturer transparency is critical and further studies are needed to expand upon the current preventative measures such as device site rotation and steroid creams, which lack consistent effectiveness.

show abstract

Laser treatment for lipoatrophy in children with diabetes type 1

Cited by 2 publications

References 14 publications

Cutaneous Adverse Effects from Diabetes Devices in Pediatric Patients with Type 1 Diabetes Mellitus: a Systematic Review (Preprint)

Cutaneous Adverse Effects from Diabetes Devices in Pediatric Patients with Type 1 Diabetes Mellitus: a Systematic Review (Preprint)

Cutaneous Adverse Effects from Diabetes Devices in Pediatric Patients with Type 1 Diabetes Mellitus: a Systematic Review (Preprint)

Contact Info

Product

Resources

About